Drugs / Autologous Tumor Cell-Based Vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00101101 | Jul 2004 → Oct 2012 | lymphoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Tumor Cell-Based Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00101101 ↗ |
| Modality | Vaccine | “vaccine comprising autologous tumor cells and GM.CD40L” NCT00101101 ↗ |
| Route | Other | “The GM.CD40L bystander vaccine administered intradermally into the bilateral axillary and inguinal nodal basins” NCT00101101 ↗ |